CRLCharles River Laboratories
$301.83+92% 1Y
$301.83
$145.5752 weeks$310.95
The financials
Charles River Laboratories by the numbers
Charles River Laboratories (CRL) reported revenue of $1.00B in Q2 2026 (quarter ended Jun 27, 2026), down 2.7% from the same quarter a year earlier. That came with net loss of $1.5M. For the full year FY2025, revenue was $4.02B (−0.9% year on year) and net income −$144M. Its largest segment in Q2 2026 was Discovery And Safety Assessment at $606M, 77% of the disclosed total, well ahead of Research Models And Services at 12%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.00B | $1.03B | −2.7% |
| Operating income | $120M | $100M | +20% |
| Net income | −$1.5M | $52M | to a loss |
| Diluted EPS | −$0.03 | $1.06 | to a loss |
| Operating | Revenue | Share |
|---|---|---|
| Discovery And Safety Assessment | $606M | 77% |
| Research Models And Services | $94M | 12% |
| Manufacturing Support | $85M | 11% |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $785.2M (+0.50%)
Discovery And Safety Assessment grew -1.9% year on yearManufacturing Support -20% year on year
Segment Latestquarter on quarteryear on year
- Discovery And Safety Assessment$605.9M$605.9Mquarter on quarter +1.6%year on year -1.9%+1.6%-1.9%
- Research Models And Services$94.4M$94.4Mquarter on quarter +0.18%year on year -3.5%+0.18%-3.5%
- Manufacturing Support$84.9M$84.9Mquarter on quarter -6.6%year on year -20%-6.6%-20%
Diagnostics & Research
The closest names by size in the same industry